Navigation Links
Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
Date:2/18/2009

CANBERRA, Australia, Feb. 18 /PRNewswire/ -- Growth is expected in Australian pharmaceuticals and life sciences market. In 2007, pharmaceuticals spending on IT accounted for 80 percent or $258.6 million and will continue to drive the growth of this market. For the same period, life sciences spending on IT accounted for $64.6 million or 20 percent of the total spending in the pharmaceuticals and life sciences market. It is expected to grow at a compound annual growth rate of around 14.3 percent from 2007 through to 2014 with potential revenues of $825.1 million in 2014.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

According to Frost & Sullivan Consulting Analyst, Sourabh Janardan Kankhar, "The pharmaceuticals industry is one of the leading exporters in the Australian manufacturing sector. At present, Australia is the 15th largest pharmaceuticals market globally. The Australian pharmaceuticals industry is expected to double its share in the world pharmaceuticals market by 2012. Currently, the Australian pharmaceuticals industry represents one percent of the world pharmaceuticals market.

Kankhar further explains, "The majority of multinational industry participants in Australia are subsidiary organisations. The leading participants include Sanofi-Aventis, Novartis, Roche, Lily, Wyeth and CSL being the largest Australian biotechnology company. Whereas, research-oriented biomedical science companies and institutes such as IDT, Zenyth, Therapeutics and Cerylid Bio Sciences often work in collaboration with hospitals, universities and other government organizations. This collaboration plays a critical role in biomedical discovery R&D and clinical trials R&D in Australia."

The cost-effective drug discovery solutions through in-silico research are driving SME life sciences companie
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation
2. Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
3. Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets
4. Frost & Sullivan - Consumer Preference for Healthy Bakery
5. Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom
6. Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC
7. Frost & Sullivan Forecasts Increased Demand for Portable and PC-based Ultrasound Units in Eastern Europe
8. Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan
9. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
10. Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
11. VTS Medical Systems, LLC Awarded Frost & Sullivan Excellence in Healthcare, Product Line Strategy Leadership Award for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 SB 277 (CA ... for children to attend public or private school. SB277 ... but bypassed the Appropriations Committee (Sacramento Bee, May 11, ... contentious hearings. , “We believe that this bill ... (PBEs) more than it will (the) affect public health ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Job satisfaction is essential ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Woman of the Year ... leadership in life coaching. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Her work as a ...
Breaking Medicine News(10 mins):Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... Pharmacologic Data Presented at American Association for Cancer Research,s ... DENVER, April 21 Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced the presentation of final data from a ... picoplatin in patients with solid tumors. Results showed that ...
... April 21 Bio-Optronics, Inc. will enhance ... with click-through integration to Interspond,s RxPaying(TM) debit ... payment alternative which improves efficiency and increases ... points in clinical trial workflow into which ...
... Scenic ride and summer weekend fun ahead in Gladstone GLADSTONE, ... Cross is teaming up with several area groups and businesses to ... with the first annual "Da, U.P. Ride for the Red" on ... Friday, July 17, local food vendors will offer their fares. Beer ...
... clopidogrel can be prescribed to patients with acute ischaemia ... (ASA). The Institute for Quality and Efficiency in Health ... clopidogrel and ASA actually has a higher benefit for ... published on 31 March 2009, concludes that combination therapy ...
... April 21 More people are turning to ... their medical condition - tattooing. A case ... the American Association of Clinical Endocrinologists (AACE) 18th ... this new phenomenon, while urging discussion from the ...
... 21 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) fiscal ... 2009. You are invited to participate in a webcast the ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Second ... released to the public after the NYSE close on Monday, May ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 3Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 4Health News:New Research Reveals Need for Doctors to Know About Medical Tattoos 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... 1, 2015 NEOVIA ONCOLOGY Ltd. ... the development and commercialization of novel, multi-function drugs ... met with the U.S. Food and Drug Administration ... an Investigational New Drug (IND) application for its ... of the meeting, Neovia has clarified details of ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3Neovia Oncology Announces First IND Meeting 2
... Feb.5 Cytopia Limited (ASX: CYT) has successfully ... for CYT997, the company,s anticancer vascular-disrupting agent (VDA). ... study have been achieved. These were to determine ... toxicities (DLTs) for the agent when administered orally ...
... (OTCBB: ORMP.OB), a developer of alternative drug,delivery systems, ... of concept,study in South Africa of insulin suppositories, ... for two visits, with,two different formulations. , ... insulin absorption and reactive,glucose lowering effect. The suppositories ...
Cached Medicine Technology:Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 2Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 3Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 4Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... An indirect immunofluorescence antibody test ... anti-neutrophil cytoplasmic antibodies (ANCA) in human ... sera of patients with necrotizing vasculitides ... to the clinical and other laboratory ...
Medicine Products: